DGX - Quest Diagnostics Incorporated
NYSE
->
Healthcare
->
Diagnostics & Research
Secaucus,
United States
Type: Equity
DGX price evolution
DGX
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $686 | $143 | $126 | $175 |
| Short term investments | ||||
| Net receivables | $1210 | $1281 | $1235 | $1254 |
| Inventory | $190 | $184 | $184 | $190 |
| Total current assets | $2372 | $1815 | $1733 | $1814 |
| Long term investments | $135 | $130 | $135 | $128 |
| Property, plant & equipment | $2418 | $2437 | $2425 | $2384 |
| Goodwill & intangible assets | $8899 | $8951 | $8980 | $8318 |
| Total noncurrent assets | $11650 | $11667 | $11692 | $10980 |
| Total investments | $135 | $130 | $135 | $128 |
| Total assets | $14022 | $13482 | $13425 | $12794 |
| Current liabilities | ||||
| Accounts payable | $1359 | $1157 | $1201 | $1198 |
| Deferred revenue | ||||
| Short long term debt | $456 | $461 | $674 | $157 |
| Total current liabilities | $1815 | $1618 | $1875 | $1355 |
| Long term debt | $4410 | $4451 | $4285 | $4465 |
| Total noncurrent liabilities | $5865 | $5401 | $5263 | $5351 |
| Total debt | $5369 | $4912 | $4959 | $4622 |
| Total liabilities | $7715 | $7019 | $7138 | $6706 |
| Shareholders' equity | ||||
| Retained earnings | $8825 | $8711 | $8566 | $8412 |
| Other shareholder equity | -$14 | -$20 | -$16 | -$18 |
| Total shareholder equity | $6307 | $6425 | $6249 | $6050 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $686 | $315 | $872 | $1158 |
| Short term investments | ||||
| Net receivables | $1210 | $1195 | $1438 | $1520 |
| Inventory | $190 | $192 | $208 | $223 |
| Total current assets | $2372 | $1898 | $2741 | $3058 |
| Long term investments | $135 | $132 | $141 | $521 |
| Property, plant & equipment | $2418 | $2351 | $2304 | $2231 |
| Goodwill & intangible assets | $8899 | $8312 | $8262 | $8040 |
| Total noncurrent assets | $11650 | $10939 | $10870 | $10968 |
| Total investments | $135 | $132 | $141 | $521 |
| Total assets | $14022 | $12837 | $13611 | $14026 |
| Current liabilities | ||||
| Accounts payable | $1359 | $1396 | $1600 | $1633 |
| Deferred revenue | ||||
| Short long term debt | $456 | $155 | $153 | $143 |
| Total current liabilities | $1815 | $1551 | $1753 | $1776 |
| Long term debt | $4410 | $3978 | $4504 | $4512 |
| Total noncurrent liabilities | $5865 | $5356 | $5375 | $5441 |
| Total debt | $5369 | $4622 | $4657 | $4655 |
| Total liabilities | $7715 | $6944 | $7128 | $7217 |
| Shareholders' equity | ||||
| Retained earnings | $8825 | $8290 | $7649 | $9303 |
| Other shareholder equity | -$14 | -$21 | -$14 | -$21 |
| Total shareholder equity | $6307 | $5893 | $6444 | $6759 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2288 | $2295 | $2338 | $2331 |
| Cost of revenue | $1541 | $1546 | $1560 | |
| Gross Profit | $740 | $754 | $792 | $771 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $380 | $416 | $439 | |
| Total operating expenses | $462 | $412 | $444 | $466 |
| Operating income | $342 | $348 | $305 | |
| Income from continuing operations | ||||
| EBIT | $333 | $347 | $302 | |
| Income tax expense | $40 | $68 | $75 | $65 |
| Interest expense | -$40 | $40 | $37 | $35 |
| Net income | ||||
| Net income | $192 | $225 | $235 | $202 |
| Income (for common shares) | $225 | $235 | $202 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9252 | $9883 | $9437 | |
| Cost of revenue | $6450 | $5804 | ||
| Gross Profit | $3069 | $3433 | $3633 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1874 | $1550 | ||
| Total operating expenses | $1764 | $2005 | $1662 | |
| Operating income | $1428 | $1971 | ||
| Income from continuing operations | ||||
| EBIT | $1348 | $2054 | ||
| Income tax expense | $248 | $264 | $460 | |
| Interest expense | -$152 | $138 | $163 | |
| Net income | ||||
| Net income | $850 | $946 | $1431 | |
| Income (for common shares) | $946 | $1431 | ||
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $225 | $235 | $202 | |
| Operating activities | ||||
| Depreciation | $111 | $112 | $107 | |
| Business acquisitions & disposals | -$2 | -$578 | -$31 | |
| Stock-based compensation | $18 | $16 | $24 | |
| Total cash flows from operations | $207 | $444 | $94 | |
| Investing activities | ||||
| Capital expenditures | -$105 | -$104 | -$127 | |
| Investments | ||||
| Total cash flows from investing | -$1061 | -$107 | -$682 | -$158 |
| Financing activities | ||||
| Dividends paid | -$314 | -$80 | -$80 | -$74 |
| Sale and purchase of stock | $13 | $22 | $25 | |
| Net borrowings | -$42 | $319 | ||
| Total cash flows from financing | $160 | -$83 | $189 | -$76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $371 | $17 | -$49 | -$140 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $946 | $1995 | $1431 | |
| Operating activities | ||||
| Depreciation | $437 | $408 | $361 | |
| Business acquisitions & disposals | -$144 | $424 | -$330 | |
| Stock-based compensation | $77 | $79 | $97 | |
| Total cash flows from operations | $1718 | $2233 | $2005 | |
| Investing activities | ||||
| Capital expenditures | -$404 | -$400 | -$415 | |
| Investments | $5 | -$3 | -$27 | |
| Total cash flows from investing | -$1061 | -$543 | $21 | -$772 |
| Financing activities | ||||
| Dividends paid | -$314 | -$305 | -$309 | -$297 |
| Sale and purchase of stock | -$1285 | -$2070 | -$136 | |
| Net borrowings | -$2 | -$2 | -$805 | |
| Total cash flows from financing | $160 | -$1732 | -$2540 | -$1267 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $371 | -$557 | -$286 | -$34 |
News
Fundamentals
| Market cap | $15.17B |
|---|---|
| Enterprise value | $19.86B |
| Shares outstanding | 111.00M |
| Revenue | $9.25B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $854.00M |
| Revenue Q/Q | -1.93% |
| Revenue Y/Y | -6.38% |
| P/E ratio | 17.77 |
|---|---|
| EV/Sales | 2.15 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.64 |
| P/B ratio | 2.40 |
| Book/Share | 56.95 |
| Cash/Share | 6.18 |
| EPS | $7.69 |
|---|---|
| ROA | 6.36% |
| ROE | 13.65% |
| Debt/Equity | 1.22 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.31 |
| Quick ratio | 1.20 |